N Schoof1, F von Bonin2, S Zeynalova3, M Ziepert3, W Jung2, M Loeffler3, M Pfreundschuh4, L Trümper2, D Kube2. 1. Department of Hematology and Oncology, Medical Center of the Georg-August-University of Göttingen, Göttingen. Electronic address: nschoof@gwdg.de. 2. Department of Hematology and Oncology, Medical Center of the Georg-August-University of Göttingen, Göttingen. 3. Department of Statistics and Epidemiology, Institute of Medical Informatics, University of Leipzig, Leipzig. 4. Department of Internal Medicine I, Saarland University, Homburg/Saar, Germany for the DSHNHL (German High-Grade Non-Hodgkin's Lymphoma Study Group).
Abstract
BACKGROUND: Recently published data indicate that host germline variations in immune genes can influence the outcome of lymphoma patients. Interleukin (IL)-4 and IL13 are crucial immune factors and may influence the course of the disease. Both cytokines signal through the interleukin-4 receptor (IL4R). Therefore, we investigated whether polymorphisms of IL4, IL13 and IL4R genes could predict the outcome of diffuse large B-cell lymphoma (DLBCL) patients. METHODS: In 228 DLBCL samples of the German High-Grade Non-Hodgkin's Lymphoma Study Group, the polymorphisms of IL4 (-524CT, rs2243250), IL13 (-1069CT, rs1800925) and IL4R (I75V, rs1805010; S503P, rs1805015; Q576R, rs1801275) were analyzed and the soluble interleukin-4 receptor (sIL4R) serum level was measured before the start of chemotherapy. RESULTS: Patients harboring IL4R V75 (IL4R(I75V-AG) and IL4R(I75V-GG)) had shorter overall survival (OS) (P = 0.044) and event-free survival (EFS) (P = 0.056) periods compared with I75 carriers (IL4R(I75V-AA)). Multivariate analysis adjusted to the International Prognostic Index revealed a relative risk of 1.9 for carriers of the IL4R V75 (P = 0.011) in relation to OS. DLBCL patients homozygous for the IL4R I75 and low sIL4R serum levels have the most favorable OS and EFS. CONCLUSIONS: These data support the role for host germline gene variations of immunologically important factors like the IL4R I75V gene variation to predict the survival in DLBCL patients.
BACKGROUND: Recently published data indicate that host germline variations in immune genes can influence the outcome of lymphomapatients. Interleukin (IL)-4 and IL13 are crucial immune factors and may influence the course of the disease. Both cytokines signal through the interleukin-4 receptor (IL4R). Therefore, we investigated whether polymorphisms of IL4, IL13 and IL4R genes could predict the outcome of diffuse large B-cell lymphoma (DLBCL) patients. METHODS: In 228 DLBCL samples of the German High-Grade Non-Hodgkin's Lymphoma Study Group, the polymorphisms of IL4 (-524CT, rs2243250), IL13 (-1069CT, rs1800925) and IL4R (I75V, rs1805010; S503P, rs1805015; Q576R, rs1801275) were analyzed and the soluble interleukin-4 receptor (sIL4R) serum level was measured before the start of chemotherapy. RESULTS:Patients harboring IL4R V75 (IL4R(I75V-AG) and IL4R(I75V-GG)) had shorter overall survival (OS) (P = 0.044) and event-free survival (EFS) (P = 0.056) periods compared with I75 carriers (IL4R(I75V-AA)). Multivariate analysis adjusted to the International Prognostic Index revealed a relative risk of 1.9 for carriers of the IL4R V75 (P = 0.011) in relation to OS. DLBCL patients homozygous for the IL4R I75 and low sIL4R serum levels have the most favorable OS and EFS. CONCLUSIONS: These data support the role for host germline gene variations of immunologically important factors like the IL4R I75V gene variation to predict the survival in DLBCL patients.
Authors: Nils Schoof; Jeremy Franklin; Robert Fürst; Thomas Zander; Frederike von Bonin; Frederic Peyrade; Lorenz Trümper; Volker Diehl; Andreas Engert; Dieter Kube; Daniel Re Journal: Oncologist Date: 2013-01-08
Authors: James L Murray; Patricia Thompson; Suk Young Yoo; Kim-Anh Do; Mala Pande; Renke Zhou; Yanhong Liu; Aysegul A Sahin; Melissa L Bondy; Abenaa M Brewster Journal: Breast Cancer Res Treat Date: 2013-03-26 Impact factor: 4.872
Authors: Kaspar René Nielsen; Rudi Steffensen; Mette Dahl Bendtsen; Maria Rodrigo-Domingo; John Baech; Thure Mors Haunstrup; Kim Steve Bergkvist; Alexander Schmitz; Julie Stoeveve Boedker; Preben Johansen; Karen Dybkaeær; Martin Boeøgsted; Hans Erik Johnsen Journal: PLoS One Date: 2015-10-08 Impact factor: 3.240